Contineum Therapeutics, Inc. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Carmine Stengone (CEO) and Peter Slover (CFO) certified on July 30, 2026 that the Q2 2026 10-Q for the period ended June 30, 2026 fairly presents the company's financial condition and complies with SEC requirements. Both officers certified the effectiveness of disclosure controls and internal controls over financial reporting, with no material weaknesses or fraud disclosed.
Why this rating
Standard SOX certification; routine quarterly compliance filing. No new transactions, business changes, or financial data disclosed in these exhibits alone.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.